Coram to Purchase Caremark's Home Infusion Therapy Business

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 3
Volume 4
Issue 3

DENVER--Coram Healthcare Corp. has reached a definitive agreement to acquire Caremark International's home infusion therapy business. Under the agreement, Caremark will receive approximately $310 million in cash and securities.

DENVER--Coram Healthcare Corp. has reached a definitive agreementto acquire Caremark International's home infusion therapy business.Under the agreement, Caremark will receive approximately $310million in cash and securities.

Recent Videos
Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.
Regardless of disease burden or disease progression speed on front-line therapy, trastuzumab deruxtecan appears effective in HER2-low breast cancer.
3 experts are featured in this series.
3 experts are featured in this series.